Multi-year agreement will use Owkin’s sophisticated AI to potentially enable Servier to develop novel therapeutics across various disease areas

多年协议将使用Owkin复杂的AI，使Servier能够在各个疾病领域开发新的治疗方法

PARIS, France and BOSTON, Mass., October 17th, 2023 – Servier, a global independent pharmaceutical group, and Owkin, a French American biotech focused on applying artificial intelligence (AI) to drug discovery, development, and diagnostics, today announced an innovative partnership to use AI to advance and accelerate better-targeted therapies across multiple disease areas, including oncology..

法国巴黎和马萨诸塞州波士顿，2023年10月17日-全球独立制药集团Servier和专注于将人工智能（AI）应用于药物发现，开发和诊断的法裔美国生物技术公司Owkin今天宣布创新合作伙伴关系，利用人工智能推进和加速包括肿瘤学在内的多个疾病领域的更好的靶向治疗。。

“I firmly believe that the convergence of scientific and medical breakthroughs, amplified by advanced technologies like AI, holds the key to swiftly introducing groundbreaking treatments that could usher in a new era of innovation for patient care” said Claude Bertrand, Executive Vice President of Research and Development and Chief Scientific Officer at Servier.

研究执行副总裁克劳德·伯特兰德（Claude Bertrand）说：“我坚信，人工智能等先进技术所扩大的科学和医学突破的融合，是迅速引入开创性治疗的关键，可以开创患者护理创新的新纪元。”Servier的发展和首席科学官。

“As an independent company, Servier can focus long-term. We look forward to partnering with Owkin to optimize our drug positioning and patient stratification to potentially bring the right treatment, to the right patient.”.

“作为一家独立公司，Servier可以长期关注。我们期待与Owkin合作，优化我们的药物定位和患者分层，以便为正确的患者带来正确的治疗。”。

“We are thrilled to partner with Servier whose primary focus is scientific development,” said Thomas Clozel, co-founder, and CEO of Owkin. “This alliance is a further proof point of the pharmaceutical industry’s readiness to innovate and to advance precision medicine using AI. Our cutting-edge tools can help our partners deliver better R&D results and better outcomes for patients with cancer and other serious diseases.”.

Owkin的联合创始人兼首席执行官Thomas Clozel说：“我们很高兴与Servier合作，后者的主要重点是科学发展。“这个联盟进一步证明了制药业准备创新和推进使用AI的精准医学，我们的尖端工具可以帮助我们的合作伙伴为癌症和其他严重疾病患者提供更好的研发成果和更好的结果。”。

The two companies will initially tackle two major challenges within translational medicine and digital pathology. Owkin will apply state-of-the-art machine learning to Servier’s extensive clinical data in order to deliver novel insights into the underlying biology of disease, identifying the patient populations most likely to benefit from Servier’s new therapies to improve patient outcomes.

这两家公司最初将应对转化医学和数字病理学方面的两大挑战。Owkin将将最先进的机器学习应用于Servier广泛的临床数据，以便为疾病的潜在生物学提供新的见解，确定最有可能从Servier的新疗法中受益的患者群体，以改善患者预后。

A multidisciplinary team of scientists, computational medicine experts and clinicians from Servier and Owkin will collaborate closely to drive the collaboration between Paris and Boston..

来自Servier和Owkin的多学科科学家，计算医学专家和临床医生团队将密切合作，推动巴黎和波士顿之间的合作。。

The first project aims to identify tumor types, tumor microenvironments, as well as de-identified patient subgroups that may optimally respond to a Servier asset. The two companies will then analyze tumor evolution to potentially identify drug combinations that may act on additional immune checkpoints or tumor cell-intrinsic mechanisms.

第一个项目旨在确定肿瘤类型，肿瘤微环境以及可能对服务资产做出最佳反应的未识别患者亚组。然后，两家公司将分析肿瘤进展，以潜在地识别可能作用于额外免疫检查点或肿瘤细胞内在机制的药物组合。

The second project will explore the implementation of digital pathology and its potential to speed upscreening and enable broader analysis of tissue-based biomarkers..

第二个项目将探讨数字病理学的实施及其加速筛查的潜力，并能够对基于组织的生物标志物进行更广泛的分析。。

Press contacts

按联系人

Owkin US/UK                                                      Owkin France

欧金美国/英国欧金法国

Edward Farmer                                                    Malika Labou

爱德华农民马利卡·拉博

edward.farmer-ext@owkin.com                         malika.labou-ext@owkin.com T: +354 863 1923                                                                       T: +33664154562

edward.farmer-ext@owkin.com                         malika.labou-ext@owkin.comT:+354 863 1923 T:+33664154562

Servier

Servier

presse@servier.com

presse@servier.com

About Servier

关于Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs.

Servier成立于服务健康，是一个全球制药集团，其基础是致力于为患者和可持续世界带来有意义的社会影响。凭借其独特的治理模式，它可以长期发挥其职业：致力于治疗进步以满足患者需求。

The 21,400 employees of the Group are committed to this shared vocation, a source of inspiration every day..

该集团的21400名员工致力于这一共同的职业，每天都是灵感的来源。。

As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting difficult and hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to Oncology. Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S.

作为心脏病学的世界领导者，Servier的雄心是通过针对难以治疗的癌症，成为肿瘤学领域的重点和创新参与者。这就是为什么该组织将超过50%的研发预算分配给肿瘤学。Servier是突变IDH抑制的领导者，是美国首次批准的突变IDH1抑制剂。

and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition..

和欧盟，该公司继续推动科学背后的目标突变IDH抑制。。

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

神经科学和免疫炎症疾病是未来的增长驱动因素。在这些领域，Servier专注于有限数量的疾病，其中准确的患者分析可以通过精准医学提供有针对性的治疗反应。为了以较低的成本促进所有人获得优质护理，该集团还依靠法国，东欧，巴西和尼日利亚的强大品牌，提供涵盖大多数病症的一系列优质仿制药。

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine..

在所有这些领域，该小组包括药物生命周期每个阶段的患者声音。。

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022.

Servier总部设在法国，在150多个国家拥有强大的地理足迹，到2022年实现了49亿欧元的收入。

For more information: servier.com

欲了解更多信息：servier.com

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

在社交媒体上关注我们：LinkedIn，Facebook，Twitter，Instagram

About Servier in oncology

关于Servier在肿瘤学

Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets..

Servier是肿瘤学领域的全球领导者，致力于为所服务的患者提供有意义的治疗进展。在非营利基金会的管理下，Servier以长期愿景实现创新，不受投资者的影响和外部压力来追逐短期货币目标。。

As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-tread cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves.

作为肿瘤学领域的领导者，Servier大大加速了对困难和难以处理的癌症的投资，其超过50%的研究和开发致力于在整个肿瘤学领域实现高度未满足需求领域的重大进展，并有可能改变它所服务的患者的生活。

Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition throughout its pipeline..

在这些领域内，Servier是突变IDH抑制的领导者，是美国和欧盟批准的第一个突变IDH抑制剂，该公司继续在其整个流程中推动科学发展。。

Servier’s commitment to therapeutic progress guides its collaboration strategy. While many companies across the industry are scaling back investments, Servier is actively building alliances, completing acquisitions, conducting licensing deals and entering new partnerships that can help to accelerate access to therapies for patients in need.

Servier对治疗进展的承诺指导其合作策略。虽然业界许多公司正在缩减投资，但Servier正在积极建立联盟，完成收购，进行许可交易并进入新的合作伙伴关系，以帮助加快有需要的患者获得治疗的机会。

With the company’s commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier is dedicated to bringing the promise of tomorrow to the patients it serves..

凭借公司的商业专业知识，全球影响力，科学专业知识和对临床卓越的承诺，Servier致力于为所服务的患者带来明天的承诺。。

About Owkin

关于Owkin

Owkin is a TechBio company that combines the best of human and artificial intelligence to ensure every patient gets the right treatment. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and develop AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI’s potential to power precision medicine.

Owkin是一家TechBio公司，结合了人类和人工智能的最佳状态，确保每位患者都能得到正确的治疗。通过AI了解复杂的生物学，我们确定新的治疗方法，降低风险并加速临床试验并开发AI诊断。Owkin使用隐私增强联合会访问最新的多模式患者数据，从而释放AI为精准医学提供动力的潜力。

We merge wet-lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation..

我们将湿实验室实验与先进的人工智能技术相结合，为加速发现和创新创造强大的反馈回路。。

Owkin founded MOSAIC, the world’s largest multi-omics atlas for cancer research.

Owkin创立了MOSAIC，这是世界上最大的癌症研究多组学地图集。

Owkin has raised over $300 million through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Owkin通过领先的生物制药公司（赛诺菲和BMS）和风险基金（Fidelity，GV和BPI等）的投资筹集了超过3亿美元。

Disclosures

披露

This release contains general information about the Servier Group and its entities (hereinafter 'Servier and its Affiliates') and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect..

本版本包含有关Servier Group及其实体（以下简称“Servier及其关联公司”）的一般信息，仅供参考。信息被认为是可靠的；但是，Servier及其关联公司对此处或其他方式提供的信息的准确性或完整性没有任何陈述，并且如果发现信息不准确，则不承担合同，侵权，过失或其他方面的责任或责任。或在任何方面不完整。。

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks..

Servier及其关联公司不作为本信息接受者的顾问，进行任何交易的最终决定仅取决于本信息的接受者。因此，在进行任何拟议交易之前，本信息的接受者应在不依赖Servier或其关联公司的情况下确定交易的经济风险和优点，以及法律，税收和会计特征和后果。并且它能够承担这些风险。。

This statement also contains forward-looking statements that are subject to varying levels of uncertainty and risk. Investigational new drugs and indications are subject to further scientific and medical review and regulatory approval. They are not approved for use by the FDA.

本声明还包含受到不同程度不确定性和风险影响的前瞻性声明。研究性新药和适应症需要进一步的科学和医学审查和监管批准。它们未被FDA批准使用。

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.

对本文档的任何依赖完全由放置此类依赖的人承担。本文档中包含的信息既不是出售报价，也不是征求报价进行交易。

The content of this document is a summary only, is not complete, and does not include all material information about Servier and its Affiliates, including potential conflicts of interest.

本文档的内容仅为摘要，不完整，不包括有关Servier及其关联公司的所有材料信息，包括潜在的利益冲突。

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor does it accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document is accurate or complete..

在适用法律法规允许的最大范围内，Servier及其关联公司不承担任何明示，暗示，法定或其他类型的陈述，保证，条件和保证，也不接受任何人对本文档的任何责任。在不影响上述一般性的情况下，Servier及其关联公司不保证或表示本文档中包含的信息或意见准确或完整。。

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same.

在适用法律法规允许的最大范围内，无论是直接还是间接，无论是合同，侵权（包括过失），严格责任，Servier及其关联公司均不对任何直接，间接，偶然，后果，本文件产生或与之相关的惩罚性或特殊损害，包括（但不限于）基于本文件采取的任何行动方案。

The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice..

本文档中表达的估算，策略和观点基于过去或当前的数据和信息，并可能在未另行通知的情况下进行更改。。